🏆 Deal of the Week · CW 45/2025
AAVantgarde Bio raised USD 141 million in a Series B round; the company's valuation was not disclosed. The round was co-led by Atlas Venture, Forbion, and new backer Schroders.
AAVantgarde Bio — key deal facts
| Company | AAVantgarde Bio |
| Founded | 2021 |
| Headquarters | Milan, Italy |
| Amount raised | USD 141m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | The raise was led by Atlas Venture, Forbion and a new backer in the form of Schroders. Other new investors who participated in the round include Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture and Willett Advisors. |
| Sectors | Biotechnology |
Who invested in AAVantgarde Bio?
Alongside the three lead investors, the round drew participation from Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors. The syndicate is notable for blending specialist life-science venture firms with corporate strategics such as Amgen Ventures and institutional asset managers including Schroders and Willett Advisors, reflecting broad cross-border conviction in the programme.
What does AAVantgarde Bio do?
AAVantgarde Bio is a clinical-stage biotechnology company founded in 2021 and headquartered in Milan, Italy. The company develops next-generation adeno-associated viral (AAV) gene therapies for inherited retinal diseases (IRDs), with lead programmes targeting Stargardt disease and Usher Syndrome Type 1B. Its proprietary AAV vector platforms are engineered to overcome the cargo-capacity constraints of standard AAV vectors, enabling delivery of large therapeutic genes to ocular tissues. The company originated as a spin-off from TIGEM (Telethon Institute of Genetics and Medicine) in Naples, co-founded by Professor Alberto Auricchio, a recognised pioneer in ocular gene therapy.
AAVantgarde Bio valuation & multiples
Explore the benchmarks: Series B.
Frequently asked questions
How much did AAVantgarde Bio raise in its Series B?
AAVantgarde Bio raised USD 141 million in its Series B round.
What is AAVantgarde Bio's valuation?
AAVantgarde Bio's valuation was not disclosed in connection with this Series B round.
Who invested in AAVantgarde Bio?
The round was co-led by Atlas Venture, Forbion, and Schroders, with additional participation from Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors.
When was AAVantgarde Bio founded and where is it based?
AAVantgarde Bio was founded in 2021 and is headquartered in Milan, Italy.
Source: original announcement — read the full report.